How GLP-1 Reduces Inflammation: Mechanisms and Evidence

GLP-1 receptor agonists such as semaglutide reduce inflammation through two routes: indirectly, by shrinking inflamed visceral fat and lowering blood sugar, and directly, by acting on GLP-1 receptors in blood vessel linings, the liver, the brain and some immune cells, which dampens NF-kB signaling and cytokines such as IL-6 and TNF-alpha. In the SELECT trial, semaglutide 2.4 mg weekly lowered high-sensitivity C-reactive protein (hsCRP) by 37.8% versus placebo over 104 weeks, and the drop began within weeks, before most weight loss, according to Plutzky and colleagues (Circulation, 2026).

That makes inflammation a real, measurable effect of this drug class. It does not yet make semaglutide an anti-inflammatory treatment in its own right: the FDA has approved it for diabetes, weight management, cardiovascular and kidney risk reduction, and a fatty liver disease called MASH, not for inflammation or autoimmune disease.

At a Glance

GLP-1 receptor agonists reduce inflammatory markers (CRP, IL-6, TNF-alpha); in SELECT, semaglutide lowered hsCRP by 37.8% versus placebo, even in people who had not lost weight (Plutzky et al., 2026).
Semaglutide reduced major cardiovascular events by 20% in SELECT (Lincoff et al., 2023), a benefit independent of weight lost (Deanfield et al., 2025); lower inflammation is one contributor.
GLP-1 receptors sit on immune cells, endothelial cells, liver cells and neurons, pointing to direct immune effects, though most mechanistic data come from cell and animal studies.
The FDA granted accelerated approval to semaglutide 2.4 mg for MASH with fibrosis in August 2025, after ESSENCE resolved liver inflammation in 63% of patients versus 34% on placebo.
Results outside metabolic disease are mixed: the EVOKE trials did not slow Alzheimer’s disease (2025), and a small liraglutide trial in psoriasis found no benefit (Faurschou et al., 2015).
These are prescription medications with real side effects; anti-inflammatory use is still investigational for most indications.

Beyond Blood Sugar and Weight Loss

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide, dulaglutide) were developed to treat type 2 diabetes by mimicking the incretin hormone GLP-1, which stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. Their dramatic weight loss effects (12-18% body weight reduction with semaglutide) made them the most talked-about drug class in a generation [1].

Clinicians also call them GLP-1 RAs, GLP-1 analogues or incretin mimetics. Tirzepatide is a dual agonist that acts on both the GIP and GLP-1 receptors, and exenatide was the first drug in the class. Compounded versions are also sold, which our compounded semaglutide guide covers in detail.

But something else showed up in the clinical trials: significant reductions in inflammatory biomarkers that could not be fully explained by weight loss alone. Researchers are now investigating whether GLP-1 agonists represent a new class of anti-inflammatory agent with applications far beyond diabetes and obesity.

The Anti-Inflammatory Evidence

Inflammatory Biomarker Reductions

Multiple trials of GLP-1 agonists have measured inflammatory markers:

High-sensitivity CRP (hsCRP): The SELECT trial (semaglutide in overweight/obese adults without diabetes but with cardiovascular disease) showed a 37.8% reduction in hsCRP compared to placebo, sustained through 104 weeks [9]. CRP is a marker of systemic inflammation and an independent predictor of cardiovascular events, a link that Ridker and colleagues have documented across large cardiovascular trials [2].
IL-6: Multiple studies show reductions in interleukin-6, a key pro-inflammatory cytokine involved in the acute-phase response and chronic inflammatory pathways.
TNF-alpha: Reductions observed in clinical studies, though the magnitude varies.
PAI-1 and fibrinogen: Reduced, suggesting decreased thrombotic risk and inflammation of the vascular endothelium.

The key finding is that these reductions exceed what would be expected from weight loss alone. In the SELECT hsCRP analysis, the fall in CRP was visible by weeks 4 and 8 and also occurred in participants who lost no weight, while placebo patients who lost similar amounts of weight did not see a CRP drop of the same size [9]. Mouse studies controlled for weight change point the same way, suggesting a direct pharmacological action on inflammatory pathways [3].

The SELECT Trial: Cardiovascular Evidence

The SELECT trial, published in the New England Journal of Medicine in 2023, was a landmark study. It enrolled 17,604 adults aged 45+ with established cardiovascular disease and overweight/obesity but without diabetes. Participants received semaglutide 2.4 mg weekly or placebo [4].

Results:

20% reduction in major adverse cardiovascular events (MACE: cardiovascular death, non-fatal MI, non-fatal stroke)
Effects emerged early (within 6-12 months) and persisted throughout a mean follow-up of 39.8 months
Cardiovascular benefit appeared before maximal weight loss occurred
A prespecified analysis in The Lancet (Deanfield et al., 2025) found the benefit was independent of baseline weight and of how much weight people lost, with about a third of it statistically linked to a smaller waist [10]
Higher baseline hsCRP predicted higher event risk, and semaglutide reduced events across every hsCRP level [9]

These analyses suggest that semaglutide’s cardiovascular protection is not explained by weight loss alone, and the Circulation authors concluded that lower inflammation contributed in part. How large that share is, next to lower blood pressure, better lipids and less visceral fat, is still unknown.

How GLP-1 Agonists Reduce Inflammation

GLP-1 agonists reduce inflammation by activating GLP-1 receptors on several tissues at once, which lowers production of inflammatory cytokines and shifts immune cells toward a calmer, repair-oriented state. They also remove some of the fuel for inflammation by reducing visceral fat, blood sugar and liver fat.

GLP-1 receptors are not limited to pancreatic beta cells. They are expressed throughout the body, including on immune cells, endothelial cells, cardiomyocytes, neurons, and hepatocytes. This widespread receptor distribution enables multiple anti-inflammatory mechanisms [5]:

Direct Immune Cell Modulation

GLP-1 receptor activation on macrophages shifts them from a pro-inflammatory M1 phenotype toward an anti-inflammatory M2 phenotype. M1 macrophages produce TNF-alpha, IL-1beta, and IL-6 (driving chronic inflammation). M2 macrophages produce IL-10 and TGF-beta (resolving inflammation and promoting tissue repair).

GLP-1 agonists also reduce T-cell activation and proliferation, decrease monocyte adhesion to endothelial cells (a key step in atherosclerotic plaque formation), and inhibit NF-kB signaling (the master regulator of inflammatory gene expression).

Endothelial Protection

GLP-1 receptor activation in endothelial cells increases nitric oxide production, reduces oxidative stress, and inhibits endothelial adhesion molecule expression (VCAM-1, ICAM-1). This makes the vascular lining less “sticky” to inflammatory cells and more resistant to atherosclerotic plaque initiation.

Adipose Tissue Inflammation

Excess visceral fat is a factory for inflammatory cytokines. GLP-1 agonists preferentially reduce visceral fat (which is more metabolically active and inflammatory than subcutaneous fat), decreasing the adipose tissue contribution to systemic inflammation. But even beyond fat reduction, GLP-1 signaling in adipocytes directly reduces cytokine secretion.

Gut Barrier and Microbiome

GLP-1 agonists improve intestinal barrier integrity, reducing bacterial endotoxin (LPS) translocation into the bloodstream. Chronic low-grade endotoxemia from a leaky gut is a recognized driver of metabolic inflammation. By strengthening the gut barrier, GLP-1 agonists address inflammation at one of its sources.

Signals Through the Brain

GLP-1 receptors on human immune cells are scarce, which has puzzled researchers. Mouse work by Drucker and colleagues at the University of Toronto suggests that part of the anti-inflammatory effect runs through GLP-1 receptors in the brain, which then quiet inflammatory responses elsewhere in the body. That finding still needs confirmation in people.

Emerging Therapeutic Applications

Non-Alcoholic Fatty Liver Disease / MASH

MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) is fundamentally an inflammatory liver disease driven by lipotoxicity and immune activation. Semaglutide has shown remarkable results: the phase II trial demonstrated histological resolution of MASH (normalization of liver inflammation) in 59% of patients compared to 17% on placebo [6].

The phase 3 ESSENCE trial confirmed the effect at scale. At 72 weeks, 62.9% of patients on semaglutide 2.4 mg had resolution of steatohepatitis without worsening fibrosis, compared with 34.3% on placebo, and 36.8% versus 22.4% had less liver scarring [11]. On that basis the FDA granted accelerated approval for MASH with moderate to advanced fibrosis in August 2025, with the trial continuing to 240 weeks to confirm effects on cirrhosis, transplant and death.

The anti-inflammatory effects in the liver go beyond weight loss, with direct hepatoprotective signaling through GLP-1 receptors on hepatocytes and Kupffer cells. MASH is currently the clearest case of a GLP-1 agonist treating an inflammatory disease, rather than simply lowering a blood marker.

Psoriasis and Psoriatic Arthritis

Psoriasis is driven by TNF-alpha, IL-17, and IL-23, and it carries a heavy symptom and quality of life burden [7]. Some observational data suggest that patients on GLP-1 agonists for diabetes have lower psoriasis flare rates than those on other diabetes medications. Case reports and small series describe psoriasis improvement in patients starting semaglutide for weight management. Clinical trials are now being designed to formally test this hypothesis.

The only placebo-controlled trial so far was small and negative. In Faurschou et al. (2015), 20 adults with plaque psoriasis and obesity took liraglutide or placebo for 8 weeks, and PASI scores, quality of life and hsCRP did not change significantly [13]. IL-17 and IL-23 biologics remain the established systemic option, as our psoriasis condition overview explains.

Osteoarthritis and Joint Pain

In the STEP 9 trial, Bliddal and colleagues (New England Journal of Medicine, 2024) found that semaglutide 2.4 mg reduced knee pain more than placebo in adults with obesity and knee osteoarthritis, but weight loss and lower joint load may explain much of that. People weighing options for osteoarthritis or rheumatoid arthritis will find no trial of GLP-1 agonists as a disease-modifying arthritis drug.

Neurodegenerative Disease

Neuroinflammation is a core feature of Alzheimer’s and Parkinson’s disease. GLP-1 receptors are expressed on neurons and microglia (the brain’s immune cells). Preclinical data shows that GLP-1 agonists reduce microglial activation, amyloid-beta deposition, and tau phosphorylation.

The large human test was disappointing. The phase 3 EVOKE and EVOKE+ trials (NCT04777396 and NCT04777409) gave oral semaglutide or placebo to 3,808 adults with early Alzheimer’s disease, and in November 2025 the sponsor reported no slowing of progression over two years. Biomarkers improved, which shows that lowering a marker does not by itself produce a clinical benefit.

Chronic Kidney Disease

The FLOW trial (2024) demonstrated that semaglutide reduced the risk of kidney disease progression by 24% in patients with type 2 diabetes and chronic kidney disease. The anti-inflammatory effects on renal tubular cells and glomerular endothelium likely contribute to this protection beyond glycemic control [8].

Heart Failure

Semaglutide improved symptoms, physical function, and exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF) and obesity in the STEP-HFpEF trial. Systemic inflammation is a key driver of HFpEF pathophysiology, and GLP-1 agonist anti-inflammatory effects likely contributed to the benefit. In that trial, CRP fell by 43.5% on semaglutide versus 7.3% on placebo at 52 weeks, according to Kosiborod and colleagues (2023) [12].

How Strong Is the Evidence in Humans?

The human evidence is strongest for lower inflammatory markers and for outcomes in heart, kidney and liver disease, and weakest for autoimmune and brain conditions. The table below sets the main trials side by side, using only the figures each study reported.

Trial	Who was studied	Result relevant to inflammation
SELECT (Lincoff 2023; Plutzky 2026)	17,604 adults with cardiovascular disease and overweight or obesity, without diabetes	hsCRP down 37.8% versus placebo at 104 weeks; major cardiovascular events down 20%
STEP-HFpEF (Kosiborod 2023)	Adults with HFpEF and obesity	CRP down 43.5% versus 7.3% on placebo at 52 weeks
ESSENCE (Sanyal 2025)	800 adults with MASH and F2 to F3 fibrosis in the first analysis	Steatohepatitis resolved in 62.9% versus 34.3% at 72 weeks
FLOW (Perkovic 2024)	Adults with type 2 diabetes and chronic kidney disease	24% lower risk of kidney disease progression
EVOKE and EVOKE+ (2025)	3,808 adults with early Alzheimer’s disease	No slowing of clinical decline despite biomarker changes
Faurschou 2015	20 adults with plaque psoriasis and obesity, 8 weeks of liraglutide	No significant change in PASI or hsCRP

GLP-1 agonists lower inflammatory markers reliably and improve outcomes where inflammation is tied to metabolic disease. In autoimmune disease and Alzheimer’s disease, results so far range from untested to negative.

Important Caveats

GLP-1 agonists are powerful medications with significant side effects that must be weighed against potential anti-inflammatory benefits:

GI side effects: Nausea, vomiting, and diarrhea affect 20-40% of patients, particularly during dose titration. Most resolve with slow titration but can be limiting.
Pancreatitis risk: Small but real increased risk of acute pancreatitis. Contraindicated in patients with a history of pancreatitis.
Gallbladder disease: Increased risk of cholelithiasis (gallstones), particularly with rapid weight loss.
Thyroid concerns: Medullary thyroid carcinoma risk observed in rodent studies (not confirmed in humans), which is why the drugs carry an FDA boxed warning. Contraindicated in patients with personal or family history of MTC or MEN2.
Muscle loss: Rapid weight loss includes lean mass loss (25-40% of total weight lost is lean mass). Resistance training and adequate protein intake are essential countermeasures.
Cost: $800-$1,500/month without insurance. Coverage is expanding but remains inconsistent, especially for obesity-only indications.

Using GLP-1 agonists purely for anti-inflammatory purposes in patients without diabetes, obesity, or cardiovascular disease is not currently supported by guidelines. The risk-benefit calculation requires a clear clinical indication. Our overview of semaglutide side effects and how they are managed goes through each risk in more depth.

Compounded semaglutide and tirzepatide are not FDA approved, the FDA has warned about dosing errors with them, and the agency declared the semaglutide shortage resolved in February 2025, which narrowed when pharmacies may compound copies.

Who Prescribes GLP-1 Agonists, and How to Find One

GLP-1 agonists are prescribed by primary care physicians, endocrinologists, cardiologists, hepatologists and obesity medicine specialists, and by nurse practitioners and physician assistants. Insurers usually cover them only for an approved use such as type 2 diabetes, obesity, cardiovascular risk, kidney disease in diabetes, or MASH.

Integrative, functional and regenerative medicine clinics often offer GLP-1 programs alongside peptide therapy, usually as cash-pay care and sometimes with compounded products. If you are comparing those programs, the national directory of peptide and GLP-1 clinics lists them by state and city. Ask who prescribes, which product is dispensed, and how side effects are followed up.

Listing order in the Regenerated.com directory is not paid ranking. Featured slots are labeled and capped, and Verified means a clinic completed credential checks, not that it paid more; the guide to Featured, Verified and organic listings sets out the details. The directory is free for patients, and inclusion is not an endorsement.

What This Means for Regenerative Health

The GLP-1 agonist story illustrates a broader principle: many chronic diseases share inflammatory roots. A drug developed for diabetes turns out to protect the heart, liver, and kidneys because chronic low-grade inflammation is a common driver of all these conditions, though the EVOKE results show that the brain is a harder case. Our explainer on chronic low-grade inflammation and its causes covers the shared biology.

For the regenerative health space, GLP-1 agonists represent a pharmacological bridge between metabolic optimization and immune modulation. They are not “natural,” but they act on physiological pathways (incretin signaling, immune cell polarization, endothelial protection) that evolution built into the body. As evidence accumulates, their role may expand beyond glucose control, with liver disease already showing what an approved inflammatory indication looks like.

Frequently asked questions

How does GLP-1 reduce inflammation?

GLP-1 agonists reduce inflammation by activating GLP-1 receptors on immune cells, blood vessel linings, liver cells and the brain, which lowers NF-kB signaling and cytokines such as IL-6 and TNF-alpha. They also shrink visceral fat, lower blood sugar and reduce liver fat, all of which feed inflammation. In SELECT, semaglutide lowered hsCRP by 37.8% versus placebo, partly before any weight loss.

Does semaglutide lower CRP?

Yes. Semaglutide 2.4 mg weekly lowered high-sensitivity CRP by 37.8% compared with placebo over 104 weeks in the SELECT trial of 17,604 adults with heart disease and excess weight. In the STEP-HFpEF heart failure trial, CRP fell 43.5% on semaglutide versus 7.3% on placebo at 52 weeks. A lower CRP does not by itself show that a specific disease is improving.

Is the anti-inflammatory effect of GLP-1 drugs just from weight loss?

No, weight loss explains only part of it. In SELECT, CRP began falling by weeks 4 to 8 and also fell in participants who lost no weight, and a 2025 Lancet analysis found the 20% drop in cardiovascular events did not depend on how much weight people lost. Less visceral fat still helps, but GLP-1 signaling appears to add an effect of its own.

Can GLP-1 agonists help autoimmune diseases like psoriasis or rheumatoid arthritis?

The evidence is thin and mixed. Observational studies and case reports describe psoriasis improving in some people taking GLP-1 drugs, but the one small placebo-controlled liraglutide trial found no significant change in psoriasis severity after 8 weeks. No completed trial has tested them as a rheumatoid arthritis or lupus treatment, and biologics and DMARDs remain the standard.

Can I get semaglutide prescribed just for inflammation?

Not under current guidelines. The FDA has approved semaglutide for type 2 diabetes, chronic weight management, cardiovascular risk reduction, kidney protection in diabetes, and MASH with liver fibrosis, but not for inflammation on its own. Using it only to lower inflammation would be off label, usually cash pay, and carries risks such as nausea, gallstones and pancreatitis without evidence of an offsetting benefit.

Sources

Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756. doi:10.1016/j.cmet.2018.03.001 ↩
Ridker PM, Lei L, Engel S, et al. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1beta inhibition with canakinumab: further rationale for the development of targeted anti-inflammatory therapies. Eur Heart J. 2020;41(23):2153-2163. doi:10.1093/eurheartj/ehz542 ↩
Rakipovski G, Rolin B, Nohr J, et al. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE-/- and LDLr-/- mice by a mechanism that includes inflammatory pathways. JACC Basic Transl Sci. 2018;3(6):844-857. doi:10.1016/j.jacbts.2018.09.004 ↩
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 ↩
Hogan AE, Gaoatswe G, Lynch L, et al. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia. 2014;57(4):781-784. doi:10.1007/s00125-013-3145-0 ↩
Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. doi:10.1056/NEJMoa2028395 ↩
Egeberg A, Loft N, Zachariae C, et al. Clinical characteristics, symptoms and burden of psoriasis and atopic dermatitis in adults. Br J Dermatol. 2020;183(1):128-138. doi:10.1111/bjd.18622 ↩
Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109-121. doi:10.1056/NEJMoa2403347 ↩
Plutzky J, et al. Effect of semaglutide on the inflammatory biomarker high-sensitivity CRP in patients with established cardiovascular disease and overweight or obesity in SELECT: a prespecified secondary analysis. Circulation. 2026;154(11):976-991. doi:10.1161/CIRCULATIONAHA.125.074482 ↩
Deanfield J, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025. doi:10.1016/S0140-6736(25)01375-3 ↩
Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025. ↩
Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069-1084. doi:10.1056/NEJMoa2306963 ↩
Faurschou A, Gyldenlove M, Rohde U, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients: a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2015;29(3):555-559. doi:10.1111/jdv.12629 ↩

GLP-1 Agonists for Inflammation: Semaglutide’s Anti-Inflammatory Potential

At a Glance

Beyond Blood Sugar and Weight Loss